Long cycle-life wound lithium-ion battery cells having metallized film current collectors
US-2024358635-A1 · Oct 31, 2024 · US
US8980940B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-8980940-B2 |
| Application number | US-201113302289-A |
| Country | US |
| Kind code | B2 |
| Filing date | Nov 22, 2011 |
| Priority date | Nov 10, 2006 |
| Publication date | Mar 17, 2015 |
| Grant date | Mar 17, 2015 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
A composition comprising a high purity cannabinoid, an acid, and a pharmaceutically-acceptable solvent achieves room temperature stability for over 24 months. The acid improves the stability of the composition and the solvent enhances the solubility of the acid, thereby allowing the acid to have an improved stabilizing effect on the highly pure cannabinoid. Preferably, the solvent is an alcohol and, more preferably, the composition contains an oil. A method for making the composition includes combining the cannabinoid and the solvent and evaporating a portion of the solvent, along with adding an acid to the composition, before, during, or after the evaporating step. A method for making and storing the composition includes storing the composition in a manner adapted to maintain its stability. Pharmaceutical dosage forms include a formulated composition, such as having the oil. A method of treating a subject comprises administering to the subject the dosage form.
Opening claim text (preview).
The invention claimed is: 1. A composition comprising a cannabinoid, an acid, an oil, and a pharmaceutically-acceptable solvent in a concentration of between about 0.001% by weight and about 2% by weight, wherein the solvent comprises a C 1 -C 4 alcohol, the acid is sufficiently soluble in the solvent to provide an amount of dissolved acid in the solvent which improves the stability of the composition and the composition is in liquid form. 2. The composition of…
Human Necessities · mapped topic
Human Necessities · mapped topic
Operations & Transport · mapped topic
Operations & Transport · mapped topic
Operations & Transport · mapped topic
Related publications grouped by family.
Free tools are coming soon. Tell us what you want to track and we'll notify you.
Answers are generated from the same data shown on this page.